High-risk Myelodysplastic Syndromes

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2022-11-10
Clinical Trial Update: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of GTB-3550 Tri-Specific Killer Engager (TriKE) for high-risk hematologic malignancies has been terminated; results posted i…